Mary Wilson
Well-known member
Published 06 March 2023
DOI https://doi.org/10.1038/s41422-023-00792-5
Zhenhao Fang, Valter S. Monteiro, Paul A. Renauer, Xingbo Shang, Kazushi Suzuki, Xinyu Ling, Meizhu Bai, Yan Xiang, Andre Levchenko, Carmen J. Booth, Carolina Lucas & Sidi Chen
Dear Editor,
The global monkeypox (Mpox) outbreak leads to a surge in demand for vaccine. The Mpox vaccine in short supply is JYNNEOS (modified vaccinia ankara, MVA) due to less side effects, while ACAM2000 supply is abundant because of the strategic stockpile in U.S.[SUP]1[/SUP] The ACAM2000 replaced the first-generation smallpox vaccine Dryvax that has a questionable safety profile. However, the ACAM2000 is associated with high rate of myocarditis and pericarditis,[SUP]1[/SUP] and can cause severe illness in immunocompromised patients, foreshadowing the need to update the strategic stockpile.
... we designed a polyvalent mRNA vaccine candidate, MPXVac-097, against 2022 Mpox in USA and characterized its immunogenicity in mice. Five MPXV antigens, A29L, E8L, M1R, A35R and B6R, were linked in tandem by 2A peptides and codon optimized. Their vaccinia homologs A27L,[SUP]5[/SUP] D8L,[SUP]5,6[/SUP] L1R,[SUP]7[/SUP]A33R[SUP]8[/SUP] and B5R[SUP]9[/SUP] have been identified as targets of neutralizing antibodies. ...
https://www.nature.com/articles/s41422-023-00792-5#citeas
DOI https://doi.org/10.1038/s41422-023-00792-5
Zhenhao Fang, Valter S. Monteiro, Paul A. Renauer, Xingbo Shang, Kazushi Suzuki, Xinyu Ling, Meizhu Bai, Yan Xiang, Andre Levchenko, Carmen J. Booth, Carolina Lucas & Sidi Chen
Dear Editor,
The global monkeypox (Mpox) outbreak leads to a surge in demand for vaccine. The Mpox vaccine in short supply is JYNNEOS (modified vaccinia ankara, MVA) due to less side effects, while ACAM2000 supply is abundant because of the strategic stockpile in U.S.[SUP]1[/SUP] The ACAM2000 replaced the first-generation smallpox vaccine Dryvax that has a questionable safety profile. However, the ACAM2000 is associated with high rate of myocarditis and pericarditis,[SUP]1[/SUP] and can cause severe illness in immunocompromised patients, foreshadowing the need to update the strategic stockpile.
... we designed a polyvalent mRNA vaccine candidate, MPXVac-097, against 2022 Mpox in USA and characterized its immunogenicity in mice. Five MPXV antigens, A29L, E8L, M1R, A35R and B6R, were linked in tandem by 2A peptides and codon optimized. Their vaccinia homologs A27L,[SUP]5[/SUP] D8L,[SUP]5,6[/SUP] L1R,[SUP]7[/SUP]A33R[SUP]8[/SUP] and B5R[SUP]9[/SUP] have been identified as targets of neutralizing antibodies. ...
https://www.nature.com/articles/s41422-023-00792-5#citeas